Build a Characterized Technology Base
Develop D016 as a defined recombinant enzyme platform with application-specific technical, manufacturing, analytical and quality requirements.
ABOUT PHARMACT
Pharmact.
Focused Biotechnology Asset Development Around D016.
Pharmact Holding AG develops and structures D016 as a recombinant hyaluronidase technology platform. The company combines technology development, evidence generation, IP governance and partnering while keeping pharmaceutical, supply / licensing and separate topical / cosmetic pathways clearly distinct.
D016TECHNOLOGY CORE
01TECHNOLOGY
DEVELOPMENT
DEVELOPMENT
02EVIDENCE
GENERATION
GENERATION
03CONTROLLED
DEVELOPMENT
DEVELOPMENT
04PARTNERING &
TRANSLATION
TRANSLATION
One technology core. Multiple controlled development interfaces.
WHAT PHARMACT DOES
Build the Asset. Generate Evidence. Define the Next Decision.
Pharmact’s role is to move a differentiated biotechnology asset through defined technical, evidentiary, regulatory and commercial decision points.
Generate Evidence Appropriate to Stage
Build technical, preclinical and regulatory-development evidence progressively and distinguish established findings from questions that remain to be tested.
Advance Through Defined Gates
Use milestone-based technical, quality, nonclinical, regulatory and commercial review before committing resources to the next development stage.
Match the Structure to the Objective
Separate material supply, technology licensing, pharmaceutical co-development and strategic transactions according to intended use, rights and development scope.
ONE TECHNOLOGY · DIFFERENT DEVELOPMENT PATHS
One Technology Core. Separate Development Paths.
D016 can support different development and commercial contexts, but the evidence, quality requirements, regulatory responsibilities and rights applicable to one pathway are not automatically transferred to another.
D016RECOMBINANT HYALURONIDASE TECHNOLOGY
BELACT® Development
Lead pharmaceutical development program built around D016, with HoFH as the planned lead orphan-development indication. BELACT remains investigational.
VIEW BELACT →Supply & Licensing
Material supply, technology licensing, co-development and strategic transactions are structured as separate engagement models with defined rights and disclosure levels.
VIEW PARTNERING →Topical / Cosmetic Development
Topical and cosmetic applications are evaluated under separate intended-use, finished-product, claims, quality and regulatory responsibilities.
Separate pathway · separate assessmentDevelopment boundary. A shared technology origin does not make pharmaceutical, industrial, supply or cosmetic pathways regulatorily interchangeable.
HOW PHARMACT WORKS
Structured Development. Defined Boundaries.
The operating model is designed to preserve scientific credibility, development optionality and controlled access to the technology.
Evidence Before Claims
Public positioning follows the evidence available for the relevant technology, application and development stage.
Do not convert possibility into established outcome.Milestone-Gated Development
Technical and regulatory uncertainty is addressed sequentially through defined evidence and decision gates.
Evidence determines the next commitment.Application-Specific Quality
Quality requirements are defined according to intended use and development context rather than assumed to be identical across pathways.
One technology does not mean one specification.Controlled Disclosure
Technical information and rights are disclosed according to qualified project scope, confidentiality and contractual structure.
Access does not itself create rights.CORPORATE & PROGRAM ROLES
Clear Roles Around One Technology Core.
Pharmact organizes technology governance, development programs, supply / partnering activities and specialist execution as distinct roles around D016.
Exact legal rights, ownership positions and transaction structures depend on the applicable entity, right and agreement. Detailed legal schedules are handled through current legal review and qualified due diligence.
VIEW INTELLECTUAL PROPERTY →Technology & Development Governance
Platform strategy, development coordination, IP governance and partner structuring around D016 and related programs.
Core Technology Asset
The recombinant hyaluronidase technology core from which application-specific development and partnering paths are structured.
Pharmaceutical Development Program
The lead pharmaceutical development program built around D016 and managed as a distinct investigational pathway.
Defined Execution Roles
Supply, manufacturing, analytical, scientific, regulatory, clinical or application-specific activities are allocated under defined project responsibilities and agreements.
DEVELOPMENT NETWORK
Specialist Expertise Is Integrated Where the Program Requires It.
Pharmact uses qualified external capabilities to execute specialized work while retaining defined project governance, evidence boundaries and decision responsibility.
The required network changes with the development stage and application. Participation in a project does not by itself imply endorsement of Pharmact, D016 or BELACT.
PHARMACTPROGRAM GOVERNANCE
MANUFACTURING &
SCALE-UP
SCALE-UP
ANALYTICS &
QUALITY
QUALITY
SCIENTIFIC &
PRECLINICAL
PRECLINICAL
REGULATORY
CLINICAL / APPLICATION
EXECUTION
EXECUTION
CORPORATE PRINCIPLE
Foresight for Life.
Foresight means structuring the next decision before committing to the next stage.
For Pharmact, this means connecting evidence, risk, rights, quality and development strategy early enough to preserve options and make deliberate decisions around biotechnology for human health.
A corporate development principle – not a product, safety, efficacy or clinical-benefit claim.
01EVIDENCE
→
02RISK
→
03DECISION
→
04TRANSLATION
U.S. CORPORATE RELATIONSHIP
A Defined U.S. Role. A Separate Legal Entity.
Pantarhin Pharma LLC is an independent U.S. company working with Pharmact in defined areas of U.S. development strategy, IP-related functions and partnering. Corporate status, rights and project-specific responsibilities remain separately defined.
INDEPENDENT U.S. PARTNER COMPANY
U.S. presence · IP-related functions · regulatory development strategy · partnering
VISIT PANTARHIN.COM →TECHNOLOGY & PARTNERING
Explore the Technology. Discuss the Right Path.
Start with the D016 technology platform or define a partnering structure according to intended use, development stage, required access and rights.